Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
FDA approves Lilly's Olumiant for pediatric patients 12 years of age and older with severe alopecia areata
U.S. Food and Drug Administration approves Lilly's Onswik , a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
U.S. FDA approves Inluriyo in combination with Verzenio for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
New Phase 3b data on Lilly's Taltz and Zepbound used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Syntholene Engages Imperial College of London Expert for Independent Technical Review of Operating Data from Iceland Demonstration Facility
QIMC Ties New Salem-Apple River Helium Zones to a Buried Basement Structure: Gravity, Magnetics and Geochemistry Converge on a Single Fault-Bounded Ramp
